Skip to main content

Articles

Page 122 of 149

  1. High systemic estrogen levels contribute to breast cancer risk for postmenopausal women, whereas low levels contribute to osteoporosis risk. Except for obesity, determinants of non-ovarian systemic estrogen le...

    Authors: Roberto Flores, Jianxin Shi, Barbara Fuhrman, Xia Xu, Timothy D Veenstra, Mitchell H Gail, Pawel Gajer, Jacques Ravel and James J Goedert
    Citation: Journal of Translational Medicine 2012 10:253
  2. Most DNA-damaging chemotherapeutic agents activate the transcription factor nuclear factor κB (NF-κB). However, NF-κB activation can either protect from or contribute to the growth suppressive effects of the a...

    Authors: Simona Caporali, Lauretta Levati, Grazia Graziani, Alessia Muzi, Maria Grazia Atzori, Enzo Bonmassar, Giuseppe Palmieri, Paolo A Ascierto and Stefania D’Atri
    Citation: Journal of Translational Medicine 2012 10:252
  3. Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell hyper-reactivity and the production of pathogenic anti-nuclear-directed auto-antibodies (Abs). B-cell ontogeny is part...

    Authors: Vincent Biajoux, Alexandre Bignon, Christelle Freitas, Valérie Martinez, Marcus Thelen, Guadalupe Lima, Juan Jakez-Ocampo, Dominique Emilie, Luis Llorente and Karl Balabanian
    Citation: Journal of Translational Medicine 2012 10:251
  4. The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our...

    Authors: Consolación Melguizo, Jose Prados, Beatriz González, Raul Ortiz, Angel Concha, Pablo Juan Alvarez, Roberto Madeddu, Gloria Perazzoli, Jaime Antonio Oliver, Rodrigo López, Fernando Rodríguez-Serrano and Antonia Aránega
    Citation: Journal of Translational Medicine 2012 10:250
  5. Epidermal growth factor receptor (EGFR) is suggested to predict the radiosensitivity and/or prognosis of human esophageal squamous cell carcinoma (ESCC). The objective of this study was to investigate the effi...

    Authors: Lei Zhao, Li-Ru He, Mian Xi, Mu-Yan Cai, Jing-Xian Shen, Qiao-Qiao Li, Yi-Ji Liao, Dong Qian, Zi-Zhen Feng, Yi-Xin Zeng, Dan Xie and Meng-Zhong Liu
    Citation: Journal of Translational Medicine 2012 10:249
  6. The use of natalizumab in multiple sclerosis (MS) may favour JC virus reactivation; this phenomenon is usually asymptomatic but can, albeit rarely, evolve into frank progressive multifocal leucoencephalopathy ...

    Authors: Roberta Mancuso, Marina Saresella, Ambra Hernis, Ivana Marventano, Cristian Ricci, Simone Agostini, Marco Rovaris, Domenico Caputo and Mario Clerici
    Citation: Journal of Translational Medicine 2012 10:248
  7. Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and pro...

    Authors: Giuseppina Bonanno, Andrea Mariotti, Annabella Procoli, Valentina Folgiero, Daniela Natale, Luca De Rosa, Ignazio Majolino, Linda Novarese, Alberto Rocci, Manuela Gambella, Marilena Ciciarello, Giovanni Scambia, Antonio Palumbo, Franco Locatelli, Raimondo De Cristofaro and Sergio Rutella
    Citation: Journal of Translational Medicine 2012 10:247
  8. Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit ...

    Authors: Thomas F Gajewski, April KS Salama, Donna Niedzwiecki, Jeffrey Johnson, Gerald Linette, Cynthia Bucher, Michelle A Blaskovich, Said M Sebti and Frank Haluska
    Citation: Journal of Translational Medicine 2012 10:246
  9. Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is cu...

    Authors: Zhi-Yuan Chen, Ming Shi, Li-Xia Peng, Wei Wei, Xin-Jian Li, Zhi-Xing Guo, Shu-Hong Li, Chong Zhong, Chao-Nan Qian and Rong-Ping Guo
    Citation: Journal of Translational Medicine 2012 10:245
  10. We tested whether apoptotic adipose-derived mesenchymal stem cells (A-ADMSCs) were superior to healthy (H)-ADMSCs at attenuating organ damage and mortality in sepsis syndrome following cecal ligation and punct...

    Authors: Chia-Lo Chang, Steve Leu, Hsin-Ching Sung, Yen-Yi Zhen, Chung-Lung Cho, Angela Chen, Tzu-Hsien Tsai, Sheng-Ying Chung, Han-Tan Chai, Cheuk-Kwan Sun, Chia-Hung Yen and Hon-Kan Yip
    Citation: Journal of Translational Medicine 2012 10:244
  11. Ischemia is the major cause of acute kidney injury (AKI), associated with high mortality and morbidity. Mesenchymal stem cells (MSCs) have multilineage differentiation potential and can be a potent therapeutic...

    Authors: Muhammad Shareef Masoud, Sanam Saiqa Anwar, Muhammad Zeeshan Afzal, Azra Mehmood, Shaheen N Khan and Sheikh Riazuddin
    Citation: Journal of Translational Medicine 2012 10:243
  12. The secretory small GTPase Rab27b was recently identified as an oncogene in breast cancer (BC) in vivo and in vitro studies. This research was designed to further explore the clinical and prognostic significan...

    Authors: Jia-Xing Zhang, Xiao-Xia Huang, Man-Bo Cai, Zhu-Ting Tong, Jie-Wei Chen, Dong Qian, Yi-Ji Liao, Hai-Xia Deng, Ding-Zhun Liao, Ma-Yan Huang, Yi-Xin Zeng, Dan Xie and Shi-Juan Mai
    Citation: Journal of Translational Medicine 2012 10:242
  13. Blood biomarkers are needed to monitor anti-angiogenic treatments for cancer. The association of blood levels of microRNAs (miRs) implicated in angiogenesis with circulating endothelial cells (CEC) and with an...

    Authors: Pierre L Triozzi, Susan Achberger, Wayne Aldrich, Arun D Singh, Ronald Grane and Ernest C Borden
    Citation: Journal of Translational Medicine 2012 10:241
  14. Disease biomarkers are defined to diagnose various phases of diseases, monitor severities of diseases and responses to therapies, or predict prognosis of patients. Disease-specific biomarkers should benefit dr...

    Authors: Xiangdong Wang and Peter A Ward
    Citation: Journal of Translational Medicine 2012 10:240

    The Retraction Note to this article has been published in Journal of Translational Medicine 2013 11:144

  15. Authors: Romain Vuillefroy de Silly, Flora Coulon, Nicolas Poirier, Vojislav Jovanovic, Sophie Brouard, Véronique Ferchaud-Roucher, Gilles Blancho and Bernard Vanhove
    Citation: Journal of Translational Medicine 2012 10(Suppl 3):P62

    This article is part of a Supplement: Volume 10 Supplement 3

  16. Authors: Emma Lindh, Johan Brännström, Petra Jones, Fredrik Wermeling, Signe Hässler, Corrado Betterle, Ben Zion Garty, Mats Stridsberg, Björn Herrmann, Mikael CI Karlsson and Ola Winqvist
    Citation: Journal of Translational Medicine 2012 10(Suppl 3):P58

    This article is part of a Supplement: Volume 10 Supplement 3

  17. Authors: Jessy Présumey, Gabriel Courties, Pascale Louis-Plence, Virginie Escriou, Daniel Scherman, Yves-Marie Pers, Hans Yssel, Jérôme Pène, Diego Kyburz, Steffen Gay, Christian Jorgensen and Florence Apparailly
    Citation: Journal of Translational Medicine 2012 10(Suppl 3):P48

    This article is part of a Supplement: Volume 10 Supplement 3

  18. Authors: Maarten R Hillen, Angela Bikker, Aike A Kruize, Marion Wenting-van Wijk, Floris PJG Lafeber, C Erik Hack, Timothy RDJ Radstake and Joel AG van Roon
    Citation: Journal of Translational Medicine 2012 10(Suppl 3):P36

    This article is part of a Supplement: Volume 10 Supplement 3

  19. Authors: Imen Habibi, Imen Sfar, Fedra Kort, Ahmed Chebil, Rim Bouraoui, Rim Limaiem, Salwa Jendoubi-Ayed, Mouna Makhlouf, Taïeb Ben Abdallah, Khaled Ayed, Leila El Matri and Yousr Gorgi
    Citation: Journal of Translational Medicine 2012 10(Suppl 3):P21

    This article is part of a Supplement: Volume 10 Supplement 3

  20. Authors: Laure Michel, Mélanie Chesneau, Philippe Manceau, Alexandra Garcia, Marion Salou, Annie Elong Ngono, Annaïck Pallier, Marylène Jacq-Foucher, Fabienne Lefrère, Sandrine Wiertlewski, Jean-Paul Soulillou, Nicolas Degauque, David-Axel Laplaud and Sophie Brouard
    Citation: Journal of Translational Medicine 2012 10(Suppl 3):O4

    This article is part of a Supplement: Volume 10 Supplement 3

Annual Journal Metrics